Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an ...

Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an ...

With Keytruda, the best-selling drug in the world, facing the end of exclusivity in 2028, BioSpace looks at five drugs that ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Osteoporosis drug Prolia faces intense competition as patents expire and generics launch Intense rivalry emerges in the ...

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.

A key state lawmaker says that the push for Oregon to set price limits on increasingly costly prescription drugs will have to ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Talks between CMS and drugmaker Amgen authorized under the Inflation Reduction Act (IRA), former President Biden's signature ...

Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.